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Abstract:  
Clostridum difficile associated diarrhoea (CDAD) is the cause of substantial mortality and 
morbidity in the developed world. However, few data are available from the developing 
world, particularly in association with HIV positivity and degree of immunosuppression. We 
investigated the prevalence of CDAD, assessing association with HIV and CD4 count, in 
medical in-patients in Malawi. In 206 patients tested for CDT 28 (14%) were positive and 
165 presented with diarrhoea. No significant  associations were seen with either diarrhoea or 
advancing HIV. 
The frequency and the clinical implications of CDAD in HIV positive and negative patients 
in SSA require further assessment. 
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Introduction: 
Clostridium difficile, a Gram-positive anaerobic spore-forming bacterium, is associated with 
chronic, persistent and recurrent diarrhoea leading to significant mortality and morbidity. It is 
currently the most common nosocomial infection in the developed world but there are few 
data from resource-poor settings and few studies have examined the frequency of  C. difficile 
associated diarrhoea (CDAD) in sub-Saharan Africa (SSA). Published prevalence rates vary 
from 0% in Zambia (Kelly et al 1996) and  0.5% in the Central African Republic (Germani et 
al., 1998) to 7.1% in children and adults in South Africa (Samie et al, 2008) and 43% in 
Nigeria. (Onwueme et al, 2011). CDAD has been described as being commonly associated 
with HIV in the developed world (Bartlett, 2007), but in SSA, only the Nigerian study found 
an association between HIV and CDAD (Onwueme et al).  
 
We examined the prevalence of Clostridium difficile toxin (CDT) in the faeces of adult 
inpatients in a Malawian hospital. We looked for possible associations of CDT positivity with 
self-reported prior antibiotic use, the presence of diarrhoea, HIV status and degree of 
immunosuppression. 
 
Materials and Methods: 
Through  2004 and2005, at Queen Elizabeth Central Hospital, Blantyre, Malawi, adults were  
recruited as part of a prospective case-controlled study on the clinical presentation and 
aetiology of diarrhoea in HIV positive and negative medical inpatients (MDS study). Of the 
471 patients approached,398 (84.5 %) were recruited and provided clinical details including 
self-reported use of antimicrobial agents prior to hospital admission. Diarrhoea was defined 
as as the passage of three or more loose or liquid stools per day (www.who.int). HIV testing 
was performed using both ‘Rapid’ HIV ELISA tests and UniGoldTM, (Trinity Biotech, 
Wicklow, Ireland) and DetermineTM H (Abbott Laboratories, Abbott Park, IL, USA). In line 
with National Aids Commission guidelines (www.aidsmalawi.org.mw), HIV infection was 
confirmed if two tests were positive and absent if both tests were negative; if test results were 
discordant, a third rapid HIV antibody test, Med Mira Rapid HIV TestTM (MedMira 
Laboratories, Halifax, Canada) was performed as a tie-breaker. HIV positive patients were 
offered a CD4 cell count, carried out at the Malawi-Liverpool Wellcome Trust (TrucountTM 
,Becton Dickinson, UK). CD4 counts were grouped as less than 50 cells/mm3, less than 200 
cells/mm3, and greater than 200 cells mm3. 
 
206 stored stool samples were subsequently available for testing for the presence of CDT. 
Faecal samples were stored in a cryotube immediately after collection and frozen and stored 
at -80°C until shipment back to the Department of Medical Microbiology, University of 
Liverpool, UK. Samples were then defrosted and tested for presence of CDT toxin using a 
validated single-step  enzyme immunoassay, according to the manufacturer’s instructions 
(TECHLAB® Tox A/B Elisa Test; www.techlab.com.))All data were entered into a secure, 
anonymised database and analysed using EPI-Info 3.3.2 and SPSS version 14. Comparisons 
between groups were performed using Fisher’s exact test.. All patients gave written informed 
consent to  participate in the study, which was approved by the College of Medicine research 
and ethics committee. . 
 
Results: 
Overall, 28/206 (13.6%) faecal samples were positive for CDT toxin. 165/206 (80%) of 
patients presented with diarrhoea (either acute or chronic in nature), of whom 22 (13.3%) 
tested positive for CDT toxin, compared to 6/35 without diarrhoea (NS). 21 (75%) of the 
CDT positive patients reported that they had purchased or used some form of antibiotic (the 
identity of which was frequently unknown) in the last month.. Of the 28 CDT positive 
patients, 21 (75%) were HIV positive, compared to 153/17 (86%) of CDT negative patients 
(p=0.16). Within the HIV positive group, there was no associations between presence of CDT 
and CD4 level. (Table 1).  
Discussion: 
This is the first study in Malawian adults to describe the presence of CDT toxin in stool 
samples. It is also the first in sub-Saharan Africa to examine possible associations of CDT 
with advancing HIV using CD4 counts. No associations were seen with diarrhoea and either 
HIV positivity or CD4 count, although significance for CD4<50 cells mm3 was almost 
reached (p=0.058). This is contrast to developed world literature (Bartlett,2007, Collini PJ et 
al, 2012), and requires further evaluation. 
Mortality associated with CDAD is greater than that from all other intestinal infectious 
diseases combined in the United States. (www.cdc.gov/HAI/organisms/cdiff), but its impact 
has not been established in the developing world setting. Risk factors for CDT, in the 
Western setting, include antibiotic exposure, age, other co-morbitities and hospitalization. 
Further evaluation is needed in the resource poor.  
Limitations of the study include a lack of detail about the types of antibiotic used by patients, 
the relative small size and possible inaccuracy of toxin testing with freezing and de-frosting. 
The limited sensitivity of a single ELISA in detecting CDT is well recognised, but should not 
affect comparison between groups within the study.  
 
Conclusions 
Despite the methodological limitations of this study, we believe it provides important 
findings. It is one of the few to examine CDT in SSA, yielding a prevalence of 14%. This 
falls somewhere between the low and nil prevalence in central and southern Africa and the 
very high rates in Nigeria.  
Despite assertions in the literature regarding the associations between CDT and HIV, based 
on a very limited evidence base, we found no association with HIV or degree of 
immunosuppression, contradicting the Nigerian findings.  
We would propose that there is a need for further randomised control studies in SSA, 
preferably incorporating culture and ribotyping of positive samples. 
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Table 1. detailing association between presentation, CDT result, HIV status and CD4 count 
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